Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 30, 2020 at 11:12 AM.

  1. #1 cafead, Sep 30, 2020 at 11:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,990
    Likes Received:
    3
    via A phase 3 trial has linked Alnylam’s lumasiran to a “clinically significant” decline in a substance that drives negative outcomes in children with a rare kidney disease. The top-line readout comes months before the FDA is due to rule on whether to approve the RNAi therapeutic in older patients.

    article source
     
    Quote

Reply to Thread